Author | Vicken Karageozian, MD

Articles

Investigational drug Luminate targets integrin receptors

Anti-integrin therapy is a promising new approach in the treatment of vitreoretinal disease. The first drug in this class, Allegro Ophthalmics’ Luminate, is in Phase 2 clinical trials for several indications, including wet age-related macular degeneration, diabetic macular edema, non-proliferative diabetic retinopathy, and vitreomacular traction.

New content coming soon, please check back later.